Your session is about to expire
← Back to Search
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody for Non-Small Cell Lung Cancer (IPSOS Trial)
IPSOS Trial Summary
This trial will compare the effectiveness of atezolizumab to chemotherapy in people with lung cancer who are not able to have platinum-doublet chemotherapy.
- Non-Small Cell Lung Cancer
IPSOS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 453 Patients • NCT03191786IPSOS Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have severe and uncontrolled pain caused by your tumor.You are currently taking antibiotics by mouth or through an IV.You are not willing to stop using traditional herbal medicines during the study.You have had serious allergic reactions to certain types of medications.You are allergic to atezolizumab or any of its ingredients.You have had another type of cancer within the last 5 years, except for certain types that have a very low risk of spreading or causing serious problems and have been successfully treated.You have a history of autoimmune disease, except for controlled Type I diabetes and hypothyroidism related to autoimmune issues.You have a history of lung diseases like idiopathic pulmonary fibrosis or drug-induced lung inflammation, or you currently have an active lung inflammation.You had a serious infection within the past month before starting the study.You are currently taking medications that weaken your immune system, such as corticosteroids or other immunosuppressants.
- Group 1: Atezolizumab
- Group 2: Single Agent Chemotherapy (Vinorelbine or Gemcitabine)
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are we still enrolling individuals for this clinical trial?
"Unfortunately, this study is not presently enrolling patients. The listing was created on September 11th, 2017 and updated as recently as September 9th, 2022. If you are seeking other studies, there are 2095 clinical trials actively searching for patients with lung cancer and 836 trials for Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody recruiting patients."
Do many different hospitals offer this research program in town?
"In addition to other research facilities, this study is being conducted at the BCCA-Vancouver Cancer Centre in Vancouver, British Columbia, the Ottawa Hospital Research Institute in Ottawa, Ontario, and the Regional health authority A vitalite health network in Moncton, New Brunswick."
Are there past examples of MPDL3280A's success in clinical trials?
"As of now, there are a total 836 clinical trials involving Atezolizumab (MPDL3280A), with 210 of those being Phase 3 studies. Many tests are performed in Woolloongabba, Queensland, but there are a total of 42411 locations where these trials take place."
Has the FDA given their okay to Atezolizumab (MPDL3280A), an antibody that targets PD-L1?
"Atezolizumab (MPDL3280A) is an antibody being trialled for efficacy and safety. So far, it has received a score of 3 from our team at Power."
What are the FDA-approved indications for Atezolizumab (MPDL3280A)?
"Atezolizumab, an antibody that has been designed to target PD-L1, is most frequently used as a treatment for metastatic ureter urothelial carcinoma. However, it can also be employed to ameliorate conditions such as locally advanced non-small cell lung cancer, recurrent cervical cancer, and malignant neoplasms."
How many people are enrolled in this clinical research project?
"Unfortunately, this research is no longer enrolling patients in the study. The trial was originally posted on September 11th, 2017 and updated for the last time on September 9th, 2022. However, there are presently 2095 clinical trials actively enrolling participants with lung cancer and 836 studies for Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody admitting patients."
Who else is applying?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger